This year, U.S. VC funding into the life sciences sector has cooled: Q1 softness was followed by a decade low in VC transactions in Q2. Despite the moderation in dealmaking volume, investors continued to deploy sizable...more
This edition of Orrick’s series of life sciences publications breaks down the record venture investment into US-based life sciences companies in 2020 and strong showing in Q1 2021. Key findings include: • US-based life...more